Stem Cell Therapies for Inflammatory Bowel Disease

Amy Lightner

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of Review: Stem cell therapies have demonstrated safety and efficacy in the treatment of perianal Crohn’s disease as compared to conventional therapy. Thus, an understanding of their place in the treatment algorithm for inflammatory bowel disease has become imperative as we move into an era of regenerative medicine. Recent Findings: There have now been over a dozen clinical trials highlighting stem cells as a useful therapeutic in Crohn’s disease. Due to the success in the local treatment for perianal Crohn’s disease, investigation is continuing in the space of targeted systemic delivery for the treatment of luminal disease. Summary: As we increase the number of patients treated in clinical trials, it is imperative to define the optimal cell donor, optimize treatment dosing and retreatment protocols, and understand methods for safely targeting and treating intraluminal disease.

Original languageEnglish (US)
Article number16
JournalCurrent gastroenterology reports
Volume21
Issue number4
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Inflammatory Bowel Diseases
Stem Cells
Crohn Disease
Therapeutics
Clinical Trials
Retreatment
Regenerative Medicine
Tissue Donors
Safety

Keywords

  • Luminal Crohn’s disease
  • Mesenchymal stem cells
  • Perianal Crohn’s disease
  • Regenerative medicine
  • Stem cells

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Stem Cell Therapies for Inflammatory Bowel Disease. / Lightner, Amy.

In: Current gastroenterology reports, Vol. 21, No. 4, 16, 01.04.2019.

Research output: Contribution to journalReview article

@article{5b1756e25e6b4b3a8eca01a168a56bc1,
title = "Stem Cell Therapies for Inflammatory Bowel Disease",
abstract = "Purpose of Review: Stem cell therapies have demonstrated safety and efficacy in the treatment of perianal Crohn’s disease as compared to conventional therapy. Thus, an understanding of their place in the treatment algorithm for inflammatory bowel disease has become imperative as we move into an era of regenerative medicine. Recent Findings: There have now been over a dozen clinical trials highlighting stem cells as a useful therapeutic in Crohn’s disease. Due to the success in the local treatment for perianal Crohn’s disease, investigation is continuing in the space of targeted systemic delivery for the treatment of luminal disease. Summary: As we increase the number of patients treated in clinical trials, it is imperative to define the optimal cell donor, optimize treatment dosing and retreatment protocols, and understand methods for safely targeting and treating intraluminal disease.",
keywords = "Luminal Crohn’s disease, Mesenchymal stem cells, Perianal Crohn’s disease, Regenerative medicine, Stem cells",
author = "Amy Lightner",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s11894-019-0672-y",
language = "English (US)",
volume = "21",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Stem Cell Therapies for Inflammatory Bowel Disease

AU - Lightner, Amy

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose of Review: Stem cell therapies have demonstrated safety and efficacy in the treatment of perianal Crohn’s disease as compared to conventional therapy. Thus, an understanding of their place in the treatment algorithm for inflammatory bowel disease has become imperative as we move into an era of regenerative medicine. Recent Findings: There have now been over a dozen clinical trials highlighting stem cells as a useful therapeutic in Crohn’s disease. Due to the success in the local treatment for perianal Crohn’s disease, investigation is continuing in the space of targeted systemic delivery for the treatment of luminal disease. Summary: As we increase the number of patients treated in clinical trials, it is imperative to define the optimal cell donor, optimize treatment dosing and retreatment protocols, and understand methods for safely targeting and treating intraluminal disease.

AB - Purpose of Review: Stem cell therapies have demonstrated safety and efficacy in the treatment of perianal Crohn’s disease as compared to conventional therapy. Thus, an understanding of their place in the treatment algorithm for inflammatory bowel disease has become imperative as we move into an era of regenerative medicine. Recent Findings: There have now been over a dozen clinical trials highlighting stem cells as a useful therapeutic in Crohn’s disease. Due to the success in the local treatment for perianal Crohn’s disease, investigation is continuing in the space of targeted systemic delivery for the treatment of luminal disease. Summary: As we increase the number of patients treated in clinical trials, it is imperative to define the optimal cell donor, optimize treatment dosing and retreatment protocols, and understand methods for safely targeting and treating intraluminal disease.

KW - Luminal Crohn’s disease

KW - Mesenchymal stem cells

KW - Perianal Crohn’s disease

KW - Regenerative medicine

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=85064005702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064005702&partnerID=8YFLogxK

U2 - 10.1007/s11894-019-0672-y

DO - 10.1007/s11894-019-0672-y

M3 - Review article

C2 - 30955111

AN - SCOPUS:85064005702

VL - 21

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 4

M1 - 16

ER -